Drugs / 225Ac-PSMA-Trillium
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06217822 | Mar 2024 → Nov 2028 expected | castration-resistant prostate carcinoma | Bayer | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-02-27 | Bayer | Results Bayer reports encouraging results for next generation investigational targeted radionuclide therapy 225Ac-PSMA-Trillium in advanced metastatic prostate cancer bayer.com ↗
The dose for expansion was successfully identified, with ≥80% of patients achieving a PSA50 response at the expansion dose. |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 225Ac-PSMA-Trillium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06217822 ↗ |
| Known as | BAY3563254 | “The study treatment 225Ac-PSMA-Trillium, also called BAY3563254, is under development to treat advanced metastatic castration-resistant prostate cancer.” NCT06217822 ↗ |
| Route | Intravenous | “Intravenous slow injection on Day 1 of a 6 week treatment cycle.” NCT06217822 ↗ |